Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the current treatment landscape for lower-risk myelodysplastic syndromes (MDS), as well as future directions for therapy. Dr Steensma highlights how the majority of low-risk MDS patients are treated with hematopoietic growth factors or lenalidomide, although certain patients will respond to immunosupressants and hypomethylating agents. He expresses his hopes for the potential of luspatercept, a recombinant fusion protein, as well as oral hypomethylating agents, the telomerase inhibitor imetelstat and splicing inhibitors.
Current landscape and future directions for lower-risk MDS treatment
